KOSPIHolding Companies044820

Cosmax BTI

₩23,250▲ 1.31%2026-11-18 close
Market Cap
₩223.3B
Turnover
₩100M
Volume
4.4K
Shares out.
9.6M
PER
2.8×
PBR
0.7×
EPS
₩8,451
Dividend Yield
3.35%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩780 per share · Prices as of the 2026-11-18 close

01

Report overview

Health Food Recovery Meets Quarterly Profit Swings

Profit attributable to owners rose for two straight years through 2025, but quarterly operating profit has fallen for two quarters since its Q1 2026 peak, so the durability of earnings is the key question.

  1. 1

    Revenue in 2025 was KRW 645.2 billion, up 8.0%, and operating profit was KRW 27 billion, up 60.7%. Both were the largest figures in 2022 to 2025.

  2. 2

    Net profit attributable to owners was KRW 29.2 billion in 2025.

  3. 3

    Quarterly revenue has increased for four straight quarters from Q4 2025 through Q3 2026, reaching KRW 241 billion in Q3 2026.

  4. 4

    Operating profit in Q3 2026 was KRW 11.8 billion, down for two consecutive quarters from the Q1 2026 peak of KRW 16.4 billion.

  5. 5

    The debt-to-equity ratio stood at 240.3% at the end of 2025, above 187.4% in 2022, leaving leverage as a burden to monitor alongside profit recovery.

02

Business structure

Cosmax BTI was created when Cosmax was spun off in 2014, and it operates as the holding company that oversees the group's subsidiaries. Its core business is health functional food ODM, supported by new business development and the operation of health food subsidiaries.

Domestic health functional food sales in 2025 were KRW 263.8 billion, up 10.89% from the prior year, while exports fell 15.39% to KRW 191.9 billion, so growth has shifted toward the home market.

Standalone revenue in 2025 was KRW 177.7 billion, up 56.56%, reflecting the liquidation of the gel mask maker Cosmax iCure and its absorption into an internal business unit. Health food subsidiary Cosmax Bio posted 2025 revenue of KRW 168.2 billion, up 14.66% from the prior year.

The pharmaceutical unit recorded 2024 sales of KRW 39.1 billion, down 17%, with an operating loss of KRW 6.3 billion. In China, the company is working with a local partner to strengthen R&D and production for the Chinese market. An Indonesian halal certification business is also under way.

As of 2025, chairwoman Seo Seong-seok is the largest shareholder and added shares through market purchases that year. The same year, the leadership roles at the group's two affiliates were switched between the sons.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩153.5B₩3.2B2.1%
2025Q4₩173.7B₩7.4B4.2%
2026Q1₩205.2B₩16.4B8.0%
2026Q2₩239B₩16.3B6.8%
2026Q3₩241B₩11.8B4.9%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩617.4B₩3.4B-₩6.5B0.6%−2.2%187.4%
2023₩628.6B₩20.2B₩9.1B3.2%3.9%248.0%
2024₩597.6B₩16.8B₩16.5B2.8%6.5%239.2%
2025₩645.2B₩27B₩29.2B4.2%10.6%240.3%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

Annual revenue rose from KRW 617.4 billion in 2022 to KRW 628.6 billion in 2023, up 1.8%, fell to KRW 597.6 billion in 2024, down 4.9%, and recovered to KRW 645.2 billion in 2025, up 8.0%.

Reports attributed the 2023 operating profit of KRW 20.2 billion to growth in health food sales from a wider overseas customer base and to cost structure improvements in health food and pharmaceuticals.

Operating profit fell to KRW 16.8 billion in 2024, down 17.1%, when the health food segment's operating profit dropped 52% to KRW 5.7 billion. Operating profit rose to KRW 27 billion in 2025, up 60.7%, and the operating margin reached 4.2%, up from 0.6% in 2022.

Net profit attributable to owners moved from a loss of KRW 6.53 billion in 2022 to a profit of KRW 9.06 billion in 2023, then to KRW 16.5 billion in 2024 and KRW 29.2 billion in 2025, up 77.5%.

Net profit including non-controlling interests was KRW 18.7 billion in 2025, below the figure attributable to owners, which suggests a loss in non-controlling interests drove the gap. Operating cash flow was KRW 35.2 billion in 2025, up from KRW 23.8 billion in 2024.

On a quarterly basis, operating profit was KRW 3.18 billion in Q3 2025 and jumped to KRW 7.36 billion in Q4 2025, up 131.4%. Q1 2026 revenue reached KRW 205.2 billion and operating profit peaked at KRW 16.4 billion, up 122.9% from the prior quarter.

Q2 2026 revenue rose to KRW 239 billion, but operating profit was flat at KRW 16.3 billion, down 0.9%. Q3 2026 revenue was KRW 241 billion, while operating profit fell to KRW 11.8 billion, down 27.5% from the prior quarter.

Net profit attributable to owners was KRW 29.3 billion in Q2 2026 and KRW 15.1 billion in Q3 2026, so quarterly owner profit did not track operating profit. Net profit attributable to owners totaled KRW 80.8 billion over the last four quarters, from Q4 2025 to Q3 2026. Total liabilities were KRW 710.7 billion at the end of 2025, against total equity of KRW 295.7 billion.

05

Industry analysis

Demand for health functional foods is recovering as wellness trends spread, according to press reports. Online channels remain dominant, with a Korea Health Functional Food Association survey showing a 71% online purchase share in 2025.

Large discount stores rose from 5.5% in 2024 to 5.9% in 2025, and drugstores rose from 0.6% to 0.7%. Convenience stores and Daiso outlets are also widening access. Indie health food brands designed by licensed professionals are gaining ground, expanding social commerce channels.

These trends create demand for ODM producers that design and manufacture products for brand owners. Cosmax, a listed cosmetics ODM company in the same group, disclosed record quarterly revenue in Q3 2026 despite the seasonally weak period.

Cosmax BTI's health food exports, however, fell 15.39% in 2025, so overseas demand has recovered more slowly than the home market. The company also exited local manufacturing at its US subsidiary and converted it into a sales entity, which lightens the fixed cost base. Market share comparisons against rival health food ODM companies are not included here.

06

Outlook

The company has said it stopped local production at its US subsidiary and will keep manufacturing only in Korea and Australia. It expects fixed cost reductions to lift profitability from 2026, which is a company statement whose effect must be confirmed in quarterly operating margins.

Operating profit was KRW 16.4 billion in Q1 2026, KRW 16.3 billion in Q2, and KRW 11.8 billion in Q3, so whether the restructuring shows up in the earnings trend is the next test. In China, a partnership with a local firm is being used to strengthen R&D and production.

In Indonesia, halal-certified products and an online channel strategy are being used to pursue local consumers. A pilot entry into B2C through a customized cosmetics platform has also been described.

Efforts to attract small indie brands include lower minimum order volumes and smart factory automation for small-batch, multi-SKU production. The 2026 annual report, the next regular filing, will show how the full-year operating margin and debt ratio were settled.

07

Valuation

PER
2.8×
PBR
0.7×
ROE
28.4%
EPS
₩8,451
BPS
₩33,688
Dividend per share
₩780

Valuation is best read against earnings scale and net asset value. Set against market capitalization, the KRW 80.8 billion of net profit attributable to owners over the last four quarters, from Q4 2025 to Q3 2026, places the multiple in a low range relative to earnings.

At the end of 2025, net assets attributable to owners stood at KRW 275.5 billion, which is larger than the current market capitalization, so the price-to-book ratio sits below 1x.

As a holding company, the group's subsidiary results flow directly into profit attributable to owners, so quarterly swings pass straight through to the multiple.

In 2025, profit attributable to owners of KRW 29.2 billion exceeded net profit of KRW 18.7 billion, so non-controlling interest results strongly affect the owner-level figure.

The debt-to-equity ratio of 240.3% at the end of 2025 is above the 187.4% recorded in 2022, so financial leverage should be read alongside the multiple. Profit has moved from a loss in 2022 to a profit in 2023 and has recovered through 2025. Operating cash flow was KRW 35.2 billion in 2025, up from KRW 23.8 billion in 2024.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Domestic health food sales growth

Domestic health food sales rose 10.89% to KRW 263.8 billion in 2025. Wider retail access and the continued online purchase share of 71% in the market support this trend. As the health food share grew, annual revenue expanded to KRW 645.2 billion in 2025.

Restructuring of the US subsidiary

The US subsidiary stopped local production and was converted into a sales entity. The company said lower fixed costs would make profitability gains visible from 2026. Reducing the production-heavy cost base could become one pillar of margin recovery.

Two consecutive years of owner profit growth

Net profit attributable to owners rose to KRW 16.5 billion in 2024 and KRW 29.2 billion in 2025. Over the last four quarters it totaled KRW 80.8 billion. In Q2 2026 it reached KRW 29.3 billion, the highest quarterly figure in the period shown.

09

Bear factors

Declining export sales

Health food exports fell 15.39% to KRW 191.9 billion in 2025, from KRW 226.8 billion. Overseas recovery is lagging domestic sales growth. Whether export channels recover will determine how sustainable top-line growth is.

Two quarters of falling operating profit

Operating profit peaked at KRW 16.4 billion in Q1 2026 and then fell to KRW 16.3 billion in Q2 and KRW 11.8 billion in Q3. The Q3 figure was down 27.5% from the prior quarter. Revenue kept rising while profit weakened, which raises questions about the durability of margin recovery.

High debt burden

The debt-to-equity ratio rose from 187.4% in 2022 to 240.3% in 2025. Total liabilities of KRW 710.7 billion at the end of 2025 are well above total equity of KRW 295.7 billion. Debt service may limit how much of the profit recovery reaches shareholders.

10

Risk factors

Earnings volatility

Profit attributable to owners and operating profit do not move in the same direction each quarter. In Q2 2026 owner profit rose to KRW 29.3 billion while operating profit was flat at KRW 16.3 billion. Non-operating items and non-controlling interest results make quarterly trends hard to read from one metric.

Governance and succession

As of 2025, chairwoman Seo Seong-seok is the largest shareholder and increased her stake through market purchases. The same year, leadership roles at the group's affiliates were switched between the sons.

Because governance is centered on the family, the link between management changes and earnings or shareholding needs to be tracked.

Overseas restructuring

Halting local production at the US subsidiary and converting it to a sales entity is expected to reduce fixed costs. The process may involve one-time costs and shifts in sales channels. Whether profitability improves as the company describes must be confirmed in quarterly results.

11

What to watch next

  1. Late March 2027

    This is when the 2026 annual report is filed. Full-year revenue, operating margin, profit attributable to owners, and debt-to-equity ratio will be disclosed as confirmed figures and can be compared with the 4.2% operating margin and 240.3% debt ratio of 2025.

  2. Around the March 2027 annual shareholders meeting

    This is the point to confirm dividend decisions and changes in the largest shareholder's stake. It also shows how the KRW 35.2 billion of 2025 operating cash flow is allocated between dividends and debt repayment.

  3. Mid-May 2027

    The Q1 2027 quarterly report is due around this time. The key checks are whether lower fixed costs after the US production halt show up in the quarterly operating margin and whether operating profit recovers from the KRW 11.8 billion level of Q3 2026.

12

Overall view

Cosmax BTI posted 2025 revenue of KRW 645.2 billion, operating profit of KRW 27 billion, and net profit attributable to owners of KRW 29.2 billion, showing a full-year recovery. Owner profit has risen for two consecutive years through 2025, and the operating margin climbed from 0.6% in 2022 to 4.2% in 2025.

Quarterly operating profit, however, peaked at KRW 16.4 billion in Q1 2026 and has fallen for two quarters, reaching KRW 11.8 billion in Q3. Domestic health food growth and the US subsidiary restructuring are the main strengths, while lower exports and a 240.3% debt-to-equity ratio are the main weaknesses.

Net profit attributable to owners of KRW 80.8 billion over the last four quarters places the multiple in a low range relative to market capitalization. The next checkpoints are the 2026 annual report and the Q1 2027 quarterly report, where the operating margin and debt ratio will show the direction of earnings.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. jasoseol.com
  2. comp.fnguide.com
  3. beautynury.com
  4. beautynury.com
  5. m.yakup.com
  6. newstomato.com
  7. jobkorea.co.kr
  8. v.daum.net
  9. view.asiae.co.kr
  10. pharmnews.com
  11. huffingtonpost.kr
  12. inthenews.co.kr
  13. digitaltoday.co.kr
  14. investing.com
  15. digitaltoday.co.kr
  16. vegannews.co.kr
  17. comp.wisereport.co.kr

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis